Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Lexeo Therapeutics (LXEO) Non Operating Income (2022 - 2026)

Lexeo Therapeutics' Non Operating Income history spans 2 years, with the latest figure at -$7000.0 for Q4 2023.

  • On a quarterly basis, Non Operating Income rose 98.86% to -$7000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $151000.0, a N/A change, with the full-year FY2025 number at $9.3 million, up 103388.89% from a year prior.
  • Non Operating Income hit -$7000.0 in Q4 2023 for Lexeo Therapeutics, down from $165000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for LXEO hit a ceiling of $427000.0 in Q3 2022 and a floor of -$614000.0 in Q4 2022.